Halfway through its Controversies, Challenges and Consensus cycle, the Charing Cross Symposium will examine this year the numerous and varied challenges currently facing the vascular and endovascular field. The Symposium will be held from 26 to 29 April 2016 at Olympia Grand, London, UK.
Studies have indicated that patterns of restenosis affect long-term outcomes following retreatment in the superficial femoral artery. Gary Ansel, OhioHealth/Riverside Methodist Hospital, Columbus, USA, presented results at the Leipzig Interventional Course (LINC; 26–29 January 2016, Leipzig, Germany) showing that, when in-stent restenosis occurs, it is more often focal with a drug-eluting stent (Zilver PTX, Cook Medical), whereas it is more diffuse with bare metal stents. The drug-eluting device, according to Ansel, yields less restenosis, less reintervention and reduced plaque burden.
The six-month results of the TOBA BTK (Tack optimised balloon angioplasty below the knee) study show that the Tack endovascular system (Intact Vascular) demonstrated high levels of primary patency, freedom from target lesion revascularisation and total freedom from amputation.
Hybrid operative thrombectomy achieves complete thrombus resolution in one operating room trip which results in reduced length of stay, bleeding complications and transfusions when compared with percutaneous treatments that use thrombolytic therapy. This can be achieved without sacrificing successful clinical or duplex results, according to data presented at the American Venous Forum (AVF; 24–26 February, Orlando, USA).
Deep vein thrombosis (DVT) refers to the formation of a blood clot (thrombus) in a deep vein in the leg. Deep vein thrombosis tends to occur in leg veins, such as the popliteal or femoral veins, as well as deep veins within the pelvis.
The formation of blood clots in the veins known as venous thromboembolism is the most common cause of preventable death in hospitals. A new study has now revealed that significant numbers of patients are not receiving recommended treatment to prevent these clots from forming - even after health care providers underwent educational programs.
One of the largest studies of its kind shows that stenting and surgery to reduce narrowing of the carotid artery and restore normal blood flow are equally effective at lowering the long-term risk of stroke.
Surgery for cardiovascular problems often requires the implantation of vascular grafts and stents to prop open failing or narrowed blood vessels. However, while this solves the immediate problem of restoring blood flow, it introduces the risk of blood clots.
Adding mechanical clot removal to clot-busting drugs could lower stroke survivors medical bills, decrease government healthcare as well as non-healthcare related costs, and increase the likelihood of the patient returning to work and participating in society, according to research presented at the American Stroke Associations International Stroke Conference 2016.
People who reach their 80s without cardiovascular disease are more likely to suffer from the effects of dementia than a heart attack or stroke, according to a study in the Journal of the American College of Cardiology. In a small group of participants, an association was also found between zero or low levels of artery-clogging calcium deposits and a low risk of dementia and cardiovascular events, suggesting that the cardiovascular risk factors that lead to coronary heart disease could also affect the brain.
LONDON, March 31, 2016 -- (Healthcare Sales & Marketing Network) -- Sirtex (SRX.AX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB)[1] stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer (hepatocellular carcinoma or HCC).
LONDON, April 1, 2016 -- (Healthcare Sales & Marketing Network) -- BTG plc (BTG.L), a global specialist healthcare company, today announced the launch of LC Bead LUMI™ in the US, the first commercially available radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ is a next generation development of LC Bead®, the market leading embolic bead.
Ethicon has announced new data from a global cardiovascular Phase III clinical trial of the Evarrest fibrin sealant patch. Seventy five per cent of patients treated during aortic reconstruction surgery with Evarrest achieved haemostasis on the first attempt within three minutes and maintained haemostasis throughout the duration of the surgery.
The Gore Excluder iliac branch endoprosthesis has become the first off-the-shelf aortic branch to be approved by the US Food and Drug Administration (FDA) according to a company release.
“Promising” results have been reported from the DANCE (Dexamethasone delivered to the adventitia to enhance clinical efficacy) trial, which is studying the Bullfrog (Mercator MedSystems) delivery of anti-inflammatory GR-agonist (dexamethasone) after atherectomy to inhibit restenosis.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos